HuGE Literature Finder
Records
1
-
30
| Risk of stroke in CYP2C19 LoF polymorphism carrier coronary artery disease patients undergoing clopidogrel therapy: An ethnicity-based updated meta-analysis. European journal of internal medicine 2021 Jun . Jafrin Sarah, Naznin Nura Ershad, Reza Md Sharif, Aziz Md Abdul, Islam Mohammad Safiq |
| Effect of CYP2C19 Genotype on Ischemic Outcomes During Oral P2Y Inhibitor Therapy: A Meta-Analysis. JACC. Cardiovascular interventions 2021 Apr 14 (7): 739-750. Pereira Naveen L, Rihal Charanjit, Lennon Ryan, Marcus Gil, Shrivastava Sanskriti, Bell Malcolm R, So Derek, Geller Nancy, Goodman Shaun G, Hasan Ahmed, Lerman Amir, Rosenberg Yves, Bailey Kent, Murad M Hassan, Farkouh Michael |
| Association of FMO3 rs1736557 polymorphism with clopidogrel response in Chinese patients with coronary artery disease. European journal of clinical pharmacology 2020 Oct . Zhu Kong-Xiang, Song Pei-Yuan, He-Li , Li Mu-Peng, Du Yin-Xiao, Ma Qi-Lin, Peng Li-Ming, Chen Xiao-Pi |
| CYP2C19, PON1, and ABCB1 gene polymorphisms in Han and Uygur populations with coronary artery disease in Northwestern Xinjiang, China, From 2014 Through 2019. Medicine 2020 Jul 99 (29): e20582. Wang Tingting, Zhao Ting, Bao Sichen, Jia Li, Feng Jie, Yu Aiping, Sun Li, Guo Xihong, Li Hongjian, Yu Luh |
Genomewide Association Study of Platelet Reactivity and Cardiovascular Response in Patients Treated With Clopidogrel: A Study by the International Clopidogrel Pharmacogenomics Consortium.
Clinical pharmacology and therapeutics 2020 May . Verma Shefali Setia, Bergmeijer Thomas O, Gong Li, Reny Jean-Luc, Lewis Joshua P, Mitchell Braxton D, Alexopoulos Dimitrios, Aradi Daniel, Altman Russ B, Bliden Kevin, Bradford Yuki, Campo Gianluca, Chang Kiyuk, Cleator John H, Déry Jean-Pierre, Dridi Nadia P, Fernandez-Cadenas Israel, Fontana Pierre, Gawaz Meinrad, Geisler Tobias, Gensini Gian Franco, Giusti Betti, Gurbel Paul A, Hochholzer Willibald, Holmvang Lene, Kim Eun-Young, Kim Ho-Sook, Marcucci Rossella, Montaner Joan, Backman Joshua D, Pakyz Ruth E, Roden Dan M, Schaeffeler Elke, Schwab Matthias, Shin Jae Gook, Siller-Matula Jolanta M, Ten Berg Jurriën M, Trenk Dietmar, Valgimigli Marco, Wallace John, Wen Ming-Shien, Kubo Michiaki, Lee Ming Ta Michael, Whaley Ryan, Winter Stefan, Klein Teri E, Shuldiner Alan R, Ritchie Marylyn D, |
| Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial. JAMA 2020 08 324 (8): 761-771. Pereira Naveen L, Farkouh Michael E, So Derek, Lennon Ryan, Geller Nancy, Mathew Verghese, Bell Malcolm, Bae Jang-Ho, Jeong Myung Ho, Chavez Ivan, Gordon Paul, Abbott J Dawn, Cagin Charles, Baudhuin Linnea, Fu Yi-Ping, Goodman Shaun G, Hasan Ahmed, Iturriaga Erin, Lerman Amir, Sidhu Mandeep, Tanguay Jean-Francois, Wang Liewei, Weinshilboum Richard, Welsh Robert, Rosenberg Yves, Bailey Kent, Rihal Charanj |
| Pharmacogenomic polygenic response score predicts ischaemic events and cardiovascular mortality in clopidogrel-treated patients. European heart journal. Cardiovascular pharmacotherapy 2019 Sep . Lewis Joshua P, Backman Joshua D, Reny Jean-Luc, Bergmeijer Thomas O, Mitchell Braxton D, Ritchie Marylyn D, Déry Jean-Pierre, Pakyz Ruth E, Gong Li, Ryan Kathleen, Kim Eun-Young, Aradi Daniel, Fernandez-Cadenas Israel, Lee Ming Ta Michael, Whaley Ryan M, Montaner Joan, Gensini Gian Franco, Cleator John H, Chang Kiyuk, Holmvang Lene, Hochholzer Willibald, Roden Dan M, Winter Stefan, Altman Russ, Alexopoulos Dimitrios, Kim Ho-Sook, Gawaz Meinrad, Bliden Kevin, Valgimigli Marco, Marcucci Rossella, Campo Gianluca, Schaeffeler Elke, Dridi Nadia P, Wen Ming-Shien, Shin Jae Gook, Fontana Pierre, Giusti Betti, Geisler Tobias, Kubo Michiaki, Trenk Dietmar, Siller-Matula Jolanta M, Ten Berg Jurriën M, Gurbel Paul A, Schwab Matthias, Klein Teri E, Shuldiner Alan |
| Impact of Platelet Endothelial Aggregation Receptor-1 Genotypes on Platelet Reactivity and Early Cardiovascular Outcomes in Patients Undergoing Percutaneous Coronary Intervention and Treated With Aspirin and Clopidogrel. Circulation. Cardiovascular interventions 2019 May 12 (5): e007019. Xu Ke, Ye Sen, Zhang Shuhua, Yang Mingwen, Zhu Tiantian, Kong Deyu, Chen Jun, Xu Lei, Li Jimin, Zhu Hui, Wang Fei, Yang Lu, Zhang Jing, Fan Yuansheng, Ying Lianghong, Hu Xianqing, Zhang Xiaofeng, Chan Noel C, Li Chunji |
| CYP2C19 genotype and adverse cardiovascular outcomes after stent implantation in clopidogrel-treated Asian populations: A systematic review and meta-analysis. Platelets 2019 30 (2): 229-240. Xi Ziwei, Fang Fang, Wang Jiayang, AlHelal Jumana, Zhou Yujie, Liu W |
| Clopidogrel utilization in patients with coronary artery disease and diabetes mellitus: should we determine CYP2C19*2 genotype? European journal of clinical pharmacology 2018 Aug . Chouchene Saoussen, Dabboubi Rym, Raddaoui Haythem, Abroug Hela, Ben Hamda Khaldoun, Hadj Fredj Sondess, Abderrazak Fatma, Gaaloul Mayssa, Rezek Marwa, Neffeti Fadoua, Hellara Ilhem, Sassi Mouna, Khefacha Linda, Sriha Asma, Nouira Semir, Najjar Mohamed Fadhel, Maatouk Faouzi, Messaoud Taieb, Hassine Mohs |
| CRISPLD1 rs12115090 polymorphisms alters antiplatelet potency of clopidogrel in coronary artery disease patients in Chinese Han. Gene 2018 Aug . Wang Jie-Ya, Zhang Yan-Jiao, Li He, Hu Xiao-Lei, Li Mu-Peng, Song Pei-Yuan, Ma Qi-Lin, Peng Li-Ming, Chen Xiao-Pi |
| CYP2C19 and ABCB1 genetic polymorphisms correlate with the recurrence of ischemic cardiovascular adverse events after clopidogrel treatment. Journal of clinical laboratory analysis 2018 Jun 32 (5): e22369. Hou Xumin, Han Wenzheng, Gan Qian, Liu Yuan, Fang Wei |
| Comparison of antiplatelet treatment in patients with clopidogrel nonresponders with or without carriage of CYP2C19 polymorphism. The Korean journal of internal medicine 2018 May . Ko Yun Myoung, Kim Jeong Kyung, Kim Jeong Hee, Park Sang-Ho, Choi Rak Kyeo |
| Response to clopidogrel and of the cytochrome CYP2C19 gene polymorphism. La Tunisie medicale 2018 Mar 96 (3): 209-218. Charfi Rim, Mzoughi Khadija, Boughalleb Miriam, Hosni Henda, Kouidhi Soumaya, Sfar Imen, Hammami Nadia, Zaïri Ihsen, Limam Manel, Zedini Chekib, Mrabet A, Klouz Anis, Gorgi Yousr, Kharrat Maher, Baccar Hédi, Trabelsi Sam |
| [Influence of CYP2C19 gene polymorphisms on the efficacy of clopidogrel treatment for the prevention of ischemic stroke following coronary stent implantation]. Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics 2017 Dec 34 (6): 839-843. Li Guode, Chen Jingjuan, Xu Zuohang, Wang Yukai, Ding Nan, Peng Lingmei, Zhang Chengguo, Shao Y |
| Variability of platelet response to clopidogrel is not related to adverse cardiovascular events in patients with stable coronary artery disease undergoing percutaneous coronary intervention. European journal of clinical pharmacology 2017 Jun . Ol?dzki Szymon, Kornacewicz-Jach Zdzis?awa, Safranow Krzysztof, Kiedrowicz Rados?aw, Gawro?ska-Szklarz Barbara, Jastrz?bska Maria, Gor?cy Jaros? |
| [Impact of CYP2C19 genotype and platelet function on clinical outcome in coronary atherosclerotic heart diseases patients received clopidogrel post percutaneous coronary intervention]. Zhonghua xin xue guan bing za zhi 2017 May 45 (5): 377-385. Wu Y, Zhang X X, Tian L, Jiang J J, Xu L, Huang Y L, Liu H, Li Y |
| CYP2C19 activity and cardiovascular risk factors in patients with an acute coronary syndrome. Medicina clinica 2017 May . Martínez-Quintana Efrén, Rodríguez-González Fayna, Medina-Gil José María, Garay-Sánchez Paloma, Tugores Anton |
| Pharmacodynamic and cytogenetic evaluation in CYP2C19*2 and CYP2C19*3 allelomorphism in South Indian population with clopidogrel therapy. International journal of cardiology 2017 Feb 229 113-118. Tantray Javeed Ahmad, Reddy K Pratap, Jamil Kaiser, Kumar Y Shi |
| Effect of cytochrome P450 2C19*17 allelic variant on cardiovascular and cerebrovascular outcomes in clopidogrel-treated patients: A systematic review and meta-analysis. Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences 2017 22 109. Huang Bo, Cui De-Jun, Ren Ying, Han Bin, Yang Da-Ping, Zhao X |
| Genotyping, Platelet Activation, and Cardiovascular Outcome in Patients after Percutaneous Coronary Intervention: Two Pieces of the Puzzle of Clopidogrel Resistance. Cardiology 2017 03 137 (2): 104-113. Siasos Gerasimos, Oikonomou Evangelos, Vavuranakis Manolis, Kokkou Eleni, Mourouzis Konstantinos, Tsalamandris Sotiris, Zaromitidou Marina, Kioufis Stamatios, Tsigkou Vasiliki, Deftereos Spyridon, Stefanadis Christodoulos, Tousoulis Dimitr |
| The effect of CYP2C19 genetic polymorphism and non-genetic factors on clopidogrel platelets inhibition in East Asian coronary artery disease patients. Thrombosis research 2017 10 158 22-24. Amin Arwa M, Sheau Chin Lim, Mohamed Noor Dzul Azri, Mostafa Hamza, Abdul Kader Muhamad Ali S K, Kah Hay Yuen, Ibrahim Baharud |
| Combination Use of Clopidogrel and Proton Pump Inhibitors Increases Major Adverse Cardiovascular Events in Patients With Coronary Artery Disease: A Meta-Analysis. Journal of cardiovascular pharmacology and therapeutics 2016 Aug . Niu Qiang, Wang Zhongsu, Zhang Yong, Wang Jiangrong, Zhang Pei, Wang Cong, Yin Xiangcui, Hou Yinglo |
| Exome sequencing of extreme clopidogrel response phenotypes identifies B4GALT2 as a determinant of on-treatment platelet reactivity. Clinical pharmacology and therapeutics 2016 May . Scott Stuart A, Collet Jean-Philippe, Baber Usman, Yang Yao, Peter Inga, Linderman Michael, Sload Jeffrey, Qiao Wanqiong, Kini Annapoorna S, Sharma Samin K, Desnick Robert J, Fuster Valentin, Hajjar Roger J, Montalescot Gilles, Hulot Jean-Sébasti |
| [Relationship between ATP-binding cassette subfamily B member 1 and cytochrome P450 2C19 polymorphisms and the effect of clopidogrel post percutaneous coronary intervention in patients with acute coronary syndrome]. Zhonghua xin xue guan bing za zhi 2016 Apr 44 (4): 309-14. Zhou C F, Ren Y H, Song Y Q, Yi J, Han B S, Xue Q, Fu Z H, Li D |
| Association between high on-treatment platelet reactivity and occurrence of cerebral ischemic events in patients undergoing percutaneous coronary intervention. Thrombosis research 2016 Feb 138 49-54. Komosa A, Siller-Matula J M, Lesiak M, Michalak M, Kowal J, M?czy?ski M, Siniawski A, Mularek-Kubzdela T, Wi?niewski S, Grajek |
| Comparison of the antiplatelet effect of clopidogrel benzene sulfonate and clopidogrel hydrogen sulfate in stable coronary heart disease. Genetics and molecular research : GMR 2016 15 (2): . Wang S H, Li X, Hou F L, Tian Y J, Liu Y H, Zheng S |
| Diabetes mellitus, CYP2C19 genotype, and response to escalating doses of clopidogrel. Insights from the ELEVATE-TIMI 56 Trial. Thrombosis and haemostasis 2016 07 116 (1): 69-77. Carreras Edward T, Hochholzer Willibald, Frelinger Andrew L, Nordio Francesco, O'Donoghue Michelle L, Wiviott Stephen D, Angiolillo Dominick J, Michelson Alan D, Sabatine Marc S, Mega Jessica |
| Effects of CYP2C19 Polymorphism on Endothelial Function, Arterial Stiffness and Inflammation in Coronary Artery Disease Patients Under Clopidogrel Treatment. Current pharmaceutical design 2015 Aug . Siasos Gerasimos, Zaromitidou Marina, Oikonomou Evangelos, Mourouzis Konstantinos, Tsalamandris Sotiris, Kioufis Stamatios, Kokkou Eleni, Zografos Theodoros, Antonopoulos Alexis, Dimitropoulos Stathis, Stefanadis Christodoulos, Papavassiliou Athanasios G, Tousoulis Dimitr |
| [The possibility of selecting optimal antiplatelet therapy in patients with coronary heart disease in terms of CYP2C19 polymorphism]. Terapevticheskii arkhiv 0 88 (5): 47-54. Bokeriya O L, Kudzoeva Z F, Shvarts V A, Koasari A K, Donakanyan S |
- Page last reviewed:Oct 1, 2021
- Page last updated:Oct 20, 2021
- Content source: